INSYS Therapeutics (INSY) Decline Appers Overdone - Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
INSYS Therapeutics (INSY) Stock Declines on Reports of Doctor Fraud
May 9, 2014 4:36 PM EDTINSYS Therapeutics (Nasdaq: INSY) stock tanked on reports a doctor in Michigan has been accused of defrauding Medicare by $7 million. The doctor is accused of writing 1,283 million prescriptions for Subsys in 5 years, 20.3% of Subsys prescribed to Medicare beneficiaries nationwide during this... More
